Enhanced Venous Thrombosis and Hypercoagulability in Murine and Human Metabolic Dysfunction-associated Steatohepatitis

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2024 Sep 21

PMID 39306095

Authors

Nilesh Pandey

Sumit Kumar Anand

Harpreet Kaur

Koral S E Richard

Lakshmi Chandaluri

Megan E Butler

Xiaolu Zhang

Brenna Pearson-Gallion

Sumati Rohilla

Sandeep Das

Tarek Magdy

Palaniappan Sethu

Kelley G Nunez

A Wayne Orr

Karen Y Stokes

Paul T Thevenot

Ari J Cohen

Oren Rom

Nirav Dhanesha

Affiliations

Soon will be listed here.

Abstract

Background: Patients with metabolic dysfunction-associated steatohepatitis (MASH) are at an increased risk of developing venous thromboembolic events, including deep vein thrombosis (DVT). To date, the study of DVT in MASH has been hampered by the lack of reliable models that mimic the pathologic aspects of human disease.

Objectives: To evaluate DVT severity and hypercoagulability in murine and human MASH.

Methods: Transcriptional changes in the liver, plasma markers of coagulation, and DVT severity were evaluated in mice fed a standard chow diet or a high-fructose, high-fat, and high-cholesterol MASH diet for 24 weeks. Plasma analyses of coagulation markers and thrombin generation assays were performed in a well-characterized cohort of patients with or without MASH.

Results: Mice fed the MASH diet developed steatohepatitis and fibrosis, mimicking human MASH. Liver RNA sequencing revealed a significant upregulation of pathways related to inflammation and coagulation concomitant with increased levels of plasma coagulation markers including increased prothrombin fragment 1+2, thrombin-antithrombin complex, plasminogen activator inhibitor-1 levels, and endothelin 1. MASH exacerbated DVT severity in mice, as evidenced by increased thrombus weight and higher thrombosis incidence (15/15 vs 11/15 in controls, P = .0317). Higher endothelin 1 release and increased apoptosis were found in endothelial cells stimulated with supernatants of palmitate-stimulated HepG2 cells. Patients with MASH exhibited increased levels of plasma coagulation markers and delayed thrombin generation.

Conclusion: We report enhanced DVT severity and hypercoagulability, both in murine and human MASH. Our model of MASH-DVT can facilitate a better understanding of the fundamental mechanisms leading to increased venous thromboembolic events in patients with MASH.

References

Lisman T, Porte R . Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010; 116(6):878-85. DOI: 10.1182/blood-2010-02-261891. View

Elvers F, Stamouli M, Adelmeijer J, Jeyanesan D, Bernal W, Maas C . In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation. J Thromb Haemost. 2023; 21(8):2078-2088. DOI: 10.1016/j.jtha.2023.03.017. View

Gomez-Lechon M, Donato M, Martinez-Romero A, Jimenez N, Castell J, OConnor J . A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2006; 165(2):106-16. DOI: 10.1016/j.cbi.2006.11.004. View

Tripodi A, Fracanzani A, Primignani M, Chantarangkul V, Clerici M, Mannucci P . Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014; 61(1):148-54. DOI: 10.1016/j.jhep.2014.03.013. View

Wolberg A, Rosendaal F, Weitz J, Jaffer I, Agnelli G, Baglin T . Venous thrombosis. Nat Rev Dis Primers. 2016; 1:15006. DOI: 10.1038/nrdp.2015.6. View

Swan D, Lisman T, Tripodi A, Thachil J . The prothrombotic tendency of metabolic-associated fatty liver disease. J Thromb Haemost. 2023; 21(11):3045-3055. DOI: 10.1016/j.jtha.2023.06.017. View

Hugenholtz G, Adelmeijer J, Meijers J, Porte R, Stravitz R, Lisman T . An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013; 58(2):752-61. DOI: 10.1002/hep.26372. View

Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M . The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2016; 117(1):139-148. DOI: 10.1160/TH16-06-0450. View

Pi X, Xie L, Patterson C . Emerging Roles of Vascular Endothelium in Metabolic Homeostasis. Circ Res. 2018; 123(4):477-494. PMC: 6205216. DOI: 10.1161/CIRCRESAHA.118.313237. View

10.

Iglesias Morcillo M, Freuer D, Peters A, Heier M, Teupser D, Meisinger C . Association between fatty liver index and blood coagulation markers: a population-based study. Lipids Health Dis. 2023; 22(1):83. PMC: 10308678. DOI: 10.1186/s12944-023-01854-8. View

11.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

12.

McMurry H, Jou J, Shatzel J . The hemostatic and thrombotic complications of liver disease. Eur J Haematol. 2021; 107(4):383-392. PMC: 9009189. DOI: 10.1111/ejh.13688. View

13.

Dhanesha N, Jain M, Doddapattar P, Undas A, Chauhan A . Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice. J Thromb Haemost. 2020; 19(3):814-821. PMC: 8527852. DOI: 10.1111/jth.15206. View

14.

Pandey N, Kaur H, Chorawala M, Anand S, Chandaluri L, Butler M . Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT. Blood Adv. 2024; 8(9):2104-2117. PMC: 11063402. DOI: 10.1182/bloodadvances.2023012282. View

15.

Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M . Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005; 41(3):553-8. DOI: 10.1002/hep.20569. View

16.

Rom O, Xu G, Guo Y, Zhu Y, Wang H, Zhang J . Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice. EBioMedicine. 2019; 41:62-72. PMC: 6444056. DOI: 10.1016/j.ebiom.2019.02.019. View

17.

Degertekin B, Ozenirler S, Elbeg S, Akyol G . The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci. 2007; 52(10):2622-8. DOI: 10.1007/s10620-006-9147-8. View

18.

Di Minno M, Tufano A, Rusolillo A, Di Minno G, Tarantino G . High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol. 2010; 16(48):6119-22. PMC: 3012581. DOI: 10.3748/wjg.v16.i48.6119. View

19.

Wan J, Roberts L, Hendrix W, Konings J, Ow T, Rabinowich L . Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. J Thromb Haemost. 2020; 18(4):834-843. PMC: 7186949. DOI: 10.1111/jth.14751. View

20.

Konigsbrugge O, Scheiner B, Simbrunner B, Semmler G, Quehenberger P, Pabinger-Fasching I . Characterization of a prothrombotic phenotype using thrombin generation and thrombin activity in cirrhosis and portal hypertension. Thromb Res. 2023; 222:124-130. DOI: 10.1016/j.thromres.2023.01.003. View